An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Completed · Phase 3

Conditions studied: Early Stage Parkinson's Disease

In brief

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial

Key facts

Study ID

NCT00335374

Run by

Solvay Pharmaceuticals

People needed

202

Starts

2007-08-01

Expected to finish

2008-11-01

Last updated by the study team

2009-02-06

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have completed S308.3.003 trial

You may not qualify if…

• Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at end of the maintenance phase (visit M6, week 24) of study S308.3.003

Where it is running

• 413 — Oceanside, California, United States
• 408 — Oxnard, California, United States
• 422 — New Haven, Connecticut, United States
• 403 — Boca Raton, Florida, United States
• 411 — Sarasota, Florida, United States
• 421 — Augusta, Georgia, United States
• 410 — Fort Wayne, Indiana, United States
• 417 — Lexington, Kentucky, United States
• 405 — Boston, Massachusetts, United States
• 420 — Boston, Massachusetts, United States
• 406 — Minneapolis, Minnesota, United States
• 412 — Raleigh, North Carolina, United States
• Site 402 — Dayton, Ohio, United States
• 303 — Bedford Park, Australia
• 304 — Cheltenham, Australia
• 301 — Concord, Australia
• Site 300 — East Gosford, Australia
• 302 — Westmead, Australia
• 315 — Kralove, Czechia
• 313 — Olomouc, Czechia
• 310 — Ostrava, Czechia
• 314 — Ostrava, Czechia
• 312 — Pardubice, Czechia
• 311 — Pilsen, Czechia
• 419 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.